Alexion's fully humanized monoclonal antibody C5 complement inhibitor (eculizumab) is being developed for the chronic rare blood disorder paroxysmal nocturnal hemoglobinuria. The Company has also performed clinical trials with eculizumab in several chronic inflammatory conditions including rheumatoid arthritis, membranous nephritis, dermatomyositis, and lupus.